Poster
High-Throughput Screening of FDA-Approved Compounds Identifies Modulators of Phagocytic Activity in iPSC-Derived Microglia
A high-throughput screen of 892 FDA-approved compounds in hiPSC-derived microglia identifies viability modulators and validates a lead compound that boosts phagocytic activity using the pHrodo assay.
Download Your Poster
"*" indicates required fields
We respect your inbox. You can unsubscribe at any time. View our privacy policy.
Inside This Poster
See screening data, compound validation, and functional assay results from a 892-compound HTS campaign in hiPSC-derived microglia built on Ricoh Biosciences' Quick-Microglia™ SeV platfo
- A primary screen of 892 FDA-approved compounds at 10 µM identified 11 candidates with z-scores above 2.0, with nearly all sharing a structurally similar functional group, supporting reproducibility of the screen.
- Secondary PrestoBlue validation of 5 shortlisted compounds at Day 7 and Day 21 confirmed Compound X as the highest-viability hit across both short-term and long-term culture periods.
- Treatment with Compound X significantly increased pHrodo fluorescence signal in MG-SeV cultures (RFU 13 ± 2.4 vs. 2.3 ± 0.81 for DMSO control), demonstrating improved phagocytic functional capacity.
Related Resources
Explore related cell models, services, and protocols connected to this application.